News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

Opinion|Videos|January 2, 2025

New FDA-Approved Treatments for PPD

Author(s)Carmen Kosicek, MSN, PMHNP-BC, Deb York, MSN, PMHNP-BC, APRN, CCRA

Panelists discuss how the recent FDA-approved treatments for postpartum depression (PPD), including zuranolone and brexanolone , offer new options for rapid symptom relief and improve the management of severe PPD cases.

Episodes in this series

EP. 1 Overview of PPD and Current Management Practices

EP. 1 Overview of PPD and Current Management Practices

EP. 2 New FDA-Approved Treatments for PPD

EP. 2 New FDA-Approved Treatments for PPD

EP. 3 The Case of a 34-Year-Old Woman With PPD After the Birth of her Third Child

EP. 3 The Case of a 34-Year-Old Woman With PPD After the Birth of her Third Child

EP. 4 Diagnostic Tools for PPD

EP. 4 Diagnostic Tools for PPD

EP. 5 Treatment Choices For PPD and Peripartum Depression

EP. 5 Treatment Choices For PPD and Peripartum Depression

EP. 6 Monitoring Treatment Response and Challenges in Managing PPD Patients in Ob/Gyn Practices

EP. 6 Monitoring Treatment Response and Challenges in Managing PPD Patients in Ob/Gyn Practices

EP. 7 A Case of PPD in a Mother With a History of Major Depressive Disorder

EP. 7 A Case of PPD in a Mother With a History of Major Depressive Disorder

EP. 8 Assessing Symptoms, Treatment Decision-Making, and Monitoring

EP. 8 Assessing Symptoms, Treatment Decision-Making, and Monitoring

EP. 9 Supporting Mothers With Postpartum Depression and Promoting Culturally Sensitive Care

EP. 9 Supporting Mothers With Postpartum Depression and Promoting Culturally Sensitive Care

postpartum depression

EP. 10 Experts Share Top 7 Recommendations for Treating Postpartum Depression

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

Concluding Thoughts: Practical Tips, Resources, and More

ByJonathan M. Meyer, MD, DLFAPA

December 8th 2025

A New Option: Getting TDM Data Faster

ByJonathan M. Meyer, MD, DLFAPA

December 1st 2025

Using TDMs to Improve Care and Communication

ByJonathan M. Meyer, MD, DLFAPA

November 20th 2025

Why Therapeutic Drug Monitoring Is Important for Antipsychotics

ByJonathan M. Meyer, MD, DLFAPA

November 13th 2025

1 KOL is featured in this series

Future Directions For Prescription Digital Therapeutics

ByGustavo Alva, MD, DFAPA,Erin Crown, MHS, PA-C, Psych-CAQ,Linda Trinh, DNP, MPH, FNP-C, PMHNP-BC

September 30th 2025

Trending on Psychiatric Times

Southern California Psychiatry: Review of New Agents in Schizophrenia and Dementia

Cobenfy for Treatment of Schizophrenia Now Approved in China

Programs for ST-905 and ST-905 for Schizophrenia and Depression Launched by Syremis Therapeutics

Latest Alzheimer Disease Data: Reports from CTAD 2025

FDA Recommends Additional Phase 3 Trial for Brilaroxazine for Schizophrenia